JP2017522278A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522278A5 JP2017522278A5 JP2016570875A JP2016570875A JP2017522278A5 JP 2017522278 A5 JP2017522278 A5 JP 2017522278A5 JP 2016570875 A JP2016570875 A JP 2016570875A JP 2016570875 A JP2016570875 A JP 2016570875A JP 2017522278 A5 JP2017522278 A5 JP 2017522278A5
- Authority
- JP
- Japan
- Prior art keywords
- pufa
- composition according
- weight
- polyunsaturated fatty
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 23
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims 7
- 229930195729 fatty acid Natural products 0.000 claims 7
- 239000000194 fatty acid Substances 0.000 claims 7
- 150000004665 fatty acids Chemical class 0.000 claims 7
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 6
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 6
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 6
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 5
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 3
- 235000021283 resveratrol Nutrition 0.000 claims 3
- 229940016667 resveratrol Drugs 0.000 claims 3
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims 2
- ITNKVODZACVXDS-YNUSHXQLSA-N ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate Chemical compound CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC ITNKVODZACVXDS-YNUSHXQLSA-N 0.000 claims 2
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims 2
- 239000008247 solid mixture Substances 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000005515 coenzyme Substances 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000419 plant extract Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14001940.7 | 2014-06-04 | ||
| EP14001940.7A EP2952180B1 (en) | 2014-06-04 | 2014-06-04 | Solid formulations containing resveratrol and omega-3 polyunsaturated fatty acids (n-3 PUFA) |
| PCT/EP2015/056530 WO2015185239A1 (en) | 2014-06-04 | 2015-03-26 | Solid formulations containing omega-3 and resveratrol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017522278A JP2017522278A (ja) | 2017-08-10 |
| JP2017522278A5 true JP2017522278A5 (enExample) | 2018-07-05 |
Family
ID=50884650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570875A Pending JP2017522278A (ja) | 2014-06-04 | 2015-03-26 | ω−３及びレスベラトロールを含む固体処方物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20170112791A1 (enExample) |
| EP (1) | EP2952180B1 (enExample) |
| JP (1) | JP2017522278A (enExample) |
| CN (1) | CN106456587B (enExample) |
| AU (1) | AU2015271278A1 (enExample) |
| CA (1) | CA2943021A1 (enExample) |
| EA (1) | EA032762B1 (enExample) |
| ES (1) | ES2615630T3 (enExample) |
| MX (1) | MX369782B (enExample) |
| PL (1) | PL2952180T3 (enExample) |
| PT (1) | PT2952180T (enExample) |
| SI (1) | SI2952180T1 (enExample) |
| UA (1) | UA119174C2 (enExample) |
| WO (1) | WO2015185239A1 (enExample) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004026950A2 (en) * | 2002-08-14 | 2004-04-01 | E.I. Du Pont De Nemours And Company | Solid flowable powder with high liquid loading |
| ITRM20020562A1 (it) | 2002-11-06 | 2004-05-07 | Sigma Tau Ind Farmaceuti | Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza. |
| WO2009034124A1 (en) * | 2007-09-12 | 2009-03-19 | Novozymes A/S | Omega-3 stabilisation towards oxidation |
| KR101100078B1 (ko) * | 2008-03-27 | 2011-12-29 | 홉킨스바이오연구센터(주) | 관절염 치료를 위한 약제학적 조성물 |
| WO2010111397A1 (en) * | 2009-03-24 | 2010-09-30 | Adds Pharmaceuticals Llc | Stabilized solubility-enhanced formulations for oral delivery |
| CN102665698A (zh) | 2009-12-23 | 2012-09-12 | 迪菲安特制药有限责任公司 | 可用于治疗心血管疾病的联合组合物 |
| WO2011120530A1 (en) | 2010-03-31 | 2011-10-06 | Lifecycle Phama A/S | Porous tablets as carriers for liquid formulations |
| IT1400695B1 (it) | 2010-06-21 | 2013-06-28 | Labomar S R L | Composizioni farmaceutiche e/o nutraceutiche contenenti principi attivi insolubili in acqua e procedimento per ottenerle. |
| CA3142049C (en) * | 2012-09-12 | 2023-08-29 | Novaliq Gmbh | Semifluorinated alkane compositions |
-
2014
- 2014-06-04 PL PL14001940T patent/PL2952180T3/pl unknown
- 2014-06-04 EP EP14001940.7A patent/EP2952180B1/en active Active
- 2014-06-04 ES ES14001940.7T patent/ES2615630T3/es active Active
- 2014-06-04 PT PT140019407T patent/PT2952180T/pt unknown
- 2014-06-04 SI SI201430151A patent/SI2952180T1/sl unknown
-
2015
- 2015-03-26 AU AU2015271278A patent/AU2015271278A1/en not_active Abandoned
- 2015-03-26 JP JP2016570875A patent/JP2017522278A/ja active Pending
- 2015-03-26 WO PCT/EP2015/056530 patent/WO2015185239A1/en not_active Ceased
- 2015-03-26 CA CA2943021A patent/CA2943021A1/en not_active Abandoned
- 2015-03-26 EA EA201692399A patent/EA032762B1/ru not_active IP Right Cessation
- 2015-03-26 US US15/316,152 patent/US20170112791A1/en not_active Abandoned
- 2015-03-26 CN CN201580029892.0A patent/CN106456587B/zh not_active Expired - Fee Related
- 2015-03-26 MX MX2016013189A patent/MX369782B/es active IP Right Grant
- 2015-03-26 UA UAA201613089A patent/UA119174C2/uk unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005089744A3 (en) | Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma | |
| JP2014512351A5 (enExample) | ||
| ES2826201T3 (es) | Cápsulas entéricas blandas que comprenden ácidos grasos poliinsaturados | |
| WO2008147562A3 (en) | Dietary formulations and methods for treatment of inflammation and other disorders | |
| JP2015143248A5 (enExample) | ||
| JP2022542513A (ja) | ω－３脂肪酸塩とボスウェリア種由来のガム樹脂の抽出物とを含む調製物 | |
| HRP20160939T1 (hr) | Pripravci za liječenje neuroloških poremećaja | |
| WO2006078457A3 (en) | Use of resolvins to treat gastrointestinal diseases | |
| ATE449057T1 (de) | Resolvine: biotemplate zur durchführung therapeutischer anwendungen | |
| HRP20161272T4 (hr) | Učinci metaboličkog utiskivanja specifično dizajnirane lipidne komponente | |
| MX2012005744A (es) | Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. | |
| RU2019110681A (ru) | Фармацевтическая композиция | |
| JP2012502090A5 (enExample) | ||
| HRP20140238T1 (hr) | Hrana za dojilje | |
| JP2007518764A5 (enExample) | ||
| WO2016040570A3 (en) | Dietary emulsion formulations and methods for using the same | |
| WO2011060944A8 (en) | Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters | |
| JP2006503031A5 (enExample) | ||
| HRP20090550T1 (hr) | UPOTREBA VISOKO KONCENTRIRANIH PRIPRAVAKA ODABRANIH n-3 MASNIH KISELINA U LIJEČENJU POREMEĆAJA SREDIŠNJEG ŽIVČANOG SUSTAVA | |
| JP2016501248A5 (enExample) | ||
| Afroze et al. | Potentials of omega-3 fatty acids as therapeutic drugs and its obstacles in the pathway: A critical review | |
| JP2015510760A5 (enExample) | ||
| RU2010121715A (ru) | Распадающаяся во рту композиция, содержащая полиненасыщенные жирные кислоты, не имеющая неприятного запаха или вкуса | |
| CA2582934A1 (en) | Composition containing omega-3 fatty acids and omega-6 fatty acids | |
| JP2017516820A5 (enExample) |